Decreased Release of the Angiogenic Peptide Vascular Endothelial Growth Factor in Alzheimer’s Disease: Recovering Effect with Insulin and DHEA Sulfate
Authors:
- Sebastiano Bruno SolerteSSSebastiano Bruno Solerte
- Ettore FerrariEFEttore Ferrari
- Gianni CuzzoniGCGianni Cuzzoni
- Eleonora LocatelliELEleonora Locatelli
- Andrea GiustinaAGAndrea Giustina
- Mauro ZamboniMZMauro Zamboni
- Nicola SchifinoNSNicola Schifino
- Mariangela RondanelliMRMariangela Rondanelli
- Carmine GazzarusoCGCarmine Gazzaruso
- Marisa FioravantiMFMarisa Fioravanti
- 1 December 2004
- journal article
- research article
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders
- Vol. 19 (1) , 1-10
Abstract
Changes of vascular endothelial growth factor (VEGF) secretion have recently been demonstrated in patients with Alzheimer’s disease (AD). Since VEGF has been involved in brain angiogenesis, neuroprotection and cerebromicrovascular exchange of substrates and nutrients, the study of VEGF could have important relapses into the pathogenesis and treatment of AD. Within this context, 35 healthy subjects (16 of young and 19 of old age), 18 patients with dementia of the vascular type (VAD) and 22 with dementia of the Alzheimer’s type (AD) were included in the study. VEGF levels were determined in the supernates of circulating natural killer (NK) immune cells isolated by immunomagnetic separation (pure CD16 + CD56 + NK cells at a final density of 7.75 × 106 cells/ml). VEGF was measured in spontaneous conditions (without modulation) and after exposure of NK cells with IL-2, lipopolysaccharide (LPS), dehydroepiandrosterone sulfate (DHEAS), LPS + insulin, amyloid-β (Aβ) fragment 1–42, the inactive sequence Aβ40–1 and Aβ1–42 + insulin. A significant decrease in VEGF released by NK cells was demonstrated in AD subjects compared to the other groups. No differences of VEGF levels were found between healthy subjects of old age and the VAD group. The incubation with LPS and DHEAS significantly increased, in a dose-dependent manner, VEGF levels in AD as well as in healthy subjects of young and old age and in VAD patients. The incubation of NK cells with Aβ1–42 completely suppressed VEGF generation in AD subjects, also reducing VEGF release in the other groups. The co-incubation of NK with LPS + insulin, at different molar concentrations, significantly restored (4- and 6-fold increase from LPS alone) VEGF in AD, also enhancing VEGF secretion in healthy subjects and the VAD group, while the co-incubation of NK with Aβ1–42 + insulin promptly abolished the negative effects of Aβ1–42 on VEGF release. These data might suggest that the decreased VEGF secretion by peripheral immune cells of AD subjects could have a negative role for brain angiogenesis, neuroprotection and for brain microvascular permeability to nutrients, increasing brain frailty towards hypoxic injuries. On the contrary, insulin and DHEAS could have beneficial effects in AD, as well as in VAD and in physiological aging, by increasing, in a dose-dependent fashion, VEGF availability by peripheral and resident immune and endothelial cells, so contributing to increase its circulating pool.Keywords
This publication has 44 references indexed in Scilit:
- Aβ42 generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3β signaling-dependent mechanismNeurobiology of Aging, 2003
- IGF-I induces vascular endothelial growth factor in human mesangial cells via a Src-dependent mechanism11See Editorial by Cooper and Thomas, p. 1584.Kidney International, 2003
- Signaling Events in Amyloid β-Peptide-induced Neuronal Death and Insulin-like Growth Factor I ProtectionJournal of Biological Chemistry, 2002
- Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer’s disease and vascular dementiaNeurobiology of Aging, 2002
- Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and plateletsScandinavian Journal of Clinical and Laboratory Investigation, 2002
- Effects of hypoxia on glial cell expression of angiogenesis-regulating factors VEGF and TGF-?Glia, 1998
- Cerebromicrovascular Pathology in Alzheimer’s Disease Compared to Normal AgingGerontology, 1997
- Activation of Immune Function by Dehydroepiandrosterone (DHEA) in Age-Advanced MenThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 1997
- Increased Expression of TGF-β1 in Brain Tissue After Ischemic Stroke in HumansStroke, 1996
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984